Voice your opinion on congressional bill HR7032-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Increasing Transparency in Generic Drug Applications Act of 2022

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

HR7667-117, S4338-117,

House committee actions Actions

Committee
Mar. 10 2022	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Mar. 09 2022	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Mar. 09 2022	Introduced in House Introduced in House

House bill HR7032-117

Increasing Transparency in Generic Drug Applications Act of 2022

Promote the cause!

Or use this QR code